Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast

被引：22
|
作者：
Krase, Ifat Zerin [1 ]
Cavanaugh, Kevin [2 ]
Curiel-Lewandrowski, Clara [2 ]
机构：
[1] Univ Arizona, Coll Med, Tucson, AZ 85724 USA
[2] Univ Arizona, Dept Dermatol, 1501 N Campbell Ave, Tucson, AZ 85724 USA
来源：
JAMA DERMATOLOGY | 2016年 / 152卷 / 03期
关键词：
D O I：
10.1001/jamadermatol.2015.3405
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：348 / 350
页数：4
相关论文
共 50 条
  • [1] A Case of Pityriasis Rubra Pilaris Treated Successfully with the Phosphodiesterase-4 Inhibitor Apremilast
    Cho, Maria
    Honda, Tetsuya
    Ueshima, Chiyuki
    Kataoka, Tatsuki
    Otsuka, Atsushi
    Kabashima, Kenji
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 (10) : 975 - 976
  • [2] Successful Treatment of Refractory Type 1 Pityriasis Rubra Pilaris With Apremilast
    Molina-Figuera, Elvira
    Gonzalez-Cantero, Alvaro
    Martinez-Lorenzo, Elena
    Sanchez-Moya, Ana-Isabel
    Garcia-Olmedo, Obdulia
    Gomez-Dorado, Blas
    Schoendorff-Ortega, Cristina
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2018, 22 (01) : 104 - 105
  • [3] Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases
    Schett, Georg
    Sloan, Victor S.
    Stevens, Randall M.
    Schafer, Peter
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2010, 2 (05) : 271 - 278
  • [4] Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis
    Abdulrahim, Hunar
    Thistleton, Samuel
    Adebajo, Adewale O.
    Shaw, Tim
    Edwards, Christopher
    Wells, Alvin
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (07) : 1099 - 1108
  • [5] Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease
    Young, Melodie
    Roebuck, Heather L.
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2016, 28 (12) : 683 - 695
  • [6] Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors
    Miguel Perez-Aso
    M. Carmen Montesinos
    Aránzazu Mediero
    Tuere Wilder
    Peter H. Schafer
    Bruce Cronstein
    Arthritis Research & Therapy, 17
  • [7] Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors
    Perez-Aso, Miguel
    Montesinos, M. Carmen
    Mediero, Aranzazu
    Wilder, Tuere
    Schafer, Peter H.
    Cronstein, Bruce
    ARTHRITIS RESEARCH & THERAPY, 2015, 17
  • [8] Discovery of Apremilast, a selective PDE4 inhibitor
    Man, Hon-Wah
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [9] Treatment of refractory pityriasis rubra pilaris with etanercept
    Conde-Taboada, Alberto
    Fueyo, Alejandro
    Lopez-Bran, Eduardo
    Pedraz, Javier
    Campos, Lucia
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB216 - AB216
  • [10] Development of an amorphous based sustained release system for apremilast a selective phosphodiesterase 4 (PDE4) inhibitor
    Zhang, Qiangnan
    Durig, Thomas
    Blass, Benjamin
    Fassihi, Reza
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2022, 615
12345